Hong Kong's Prenetics Q1 revenue quadruples on IM8 growth

Prenetics Global

14/05/2026 13:12

Overview

Hong Kong consumer health firm's preliminary Q1 revenue jumped over 4x yr/yr, driven by IM8 growth

Preliminary Q1 adjusted EBITDA loss widened

Company raised full-year IM8 revenue guidance and executed $19 mln of $40 mln buyback

Outlook

Prenetics raises full-year 2026 IM8 revenue guidance to $190 mln-$210 mln (prior $180 mln-$200 mln)

Company projects Q2 2026 revenue of $46 mln-$48 mln, with IM8 contributing $44 mln-$46 mln

Prenetics expects to maintain gross margin efficiencies through the balance of 2026

Result Drivers

IM8 REVENUE GROWTH - IM8 revenue rose 23% sequentially and over 6x yr/yr, driven by global expansion and increased product-market fit

SUBSCRIPTION STRATEGY - Broader adoption of quarterly subscription plans led to higher average order values and consolidated customer orders

MARGIN EXPANSION - Gross margin improved to 64% from 60% qtr/qtr, attributed to manufacturing efficiencies, renegotiated supplier terms, and favorable product mix

Company press release: ID:nGNX7XjQsy

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$36 mln
Q1 Adjusted EBITDA
-$5.60 mln
Q1 Gross Margin
64.00%
Q1 Income from Operations
-$8.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Prenetics Global Ltd is $30.00, about 70.7% above its May 13 closing price of $17.57

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)